Search research articles
Contact Us
Filters
Showing results (141-150 of 157) with videos related to
Page
of 16
Sort By:
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Frontiers in Pharmacology
|
October 14, 2016
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study
Carmine D'Aniello, Maria G Vitale, Azzurra Farnesi, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
JCO Global Oncology
|
October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Francesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Frontiers in Oncology
|
August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Maria T Bourlon, Luca Galli, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Scientific Reports
|
June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis
Brigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
Journal of Translational Medicine
|
August 30, 2019
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
Gaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, et al.
JAMA Network Open
|
October 28, 2020
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Sabine Schmid, Aurelius Omlin, Celestia Higano, et al.
Cancers
|
July 27, 2024
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
Enrique Perez-Navarro, Vincenza Conteduca, Juan M Funes, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 157) with videos related to
Sort By:
Page
of 16
European Urology Open Science
|
November 24, 2025
Efficacy of Enfortumab Vedotin After Platinum Chemotherapy and Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Real-World Analysis of the ARON-2EV Cohort
Ondrej Fiala, Francesco Grillone, Kazutoshi Fujita, et al.
Frontiers in Pharmacology
|
October 14, 2016
Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study
Carmine D'Aniello, Maria G Vitale, Azzurra Farnesi, et al.
Clinical & Experimental Metastasis
|
February 20, 2025
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2<sup>EV</sup> study
Ondřej Fiala, Sebastiano Buti, Kazutoshi Fujita, et al.
JCO Global Oncology
|
October 29, 2025
Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study
Francesco Massari, Matteo Rosellini, Bohuslav Melichar, et al.
Frontiers in Oncology
|
August 11, 2025
Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study
Maria T Bourlon, Luca Galli, Enrique Grande, et al.
Cancer Immunology, Immunotherapy : CII
|
November 14, 2025
Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study
Ray Manneh Kopp, Francesco Massari, Enrique Grande, et al.
Scientific Reports
|
June 17, 2026
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis
Brigida Anna Maiorano, Giandomenico Roviello, Alessandro Rizzo, et al.
Journal of Translational Medicine
|
August 30, 2019
Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
Gaetano Facchini, Sabrina Rossetti, Massimiliano Berretta, et al.
JAMA Network Open
|
October 28, 2020
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations
Sabine Schmid, Aurelius Omlin, Celestia Higano, et al.
Cancers
|
July 27, 2024
Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer
Enrique Perez-Navarro, Vincenza Conteduca, Juan M Funes, et al.
Page
of 16